Adipotide
Prohibitin-targeting peptide 1 (Prohibitin-TP01)
Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.
Complete Research Database
Primate Efficacy Study
View StudyAdipotide for Targeted Fat Reduction in Rhesus Monkeys
PRIMARY RESULTS
14.7% weight loss with high dose, 38.7% fat mass reduction
KEY FINDINGS
- •Selective targeting of white adipose tissue
- •Significant weight loss in primate model
- •Reversible kidney function changes observed
Phase I Human Trial
View StudySafety Study in Cancer Patients with Obesity
PRIMARY RESULTS
Trial discontinued due to nephrotoxicity concerns
KEY FINDINGS
- •Development halted due to kidney safety signals
- •Promising efficacy but unacceptable risk profile
- •Led to discontinuation of clinical program
Medical Disclaimer
CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.